Gentler transplant approach aims to beat blood cancers with fewer side effects

NCT ID NCT05417971

Recruiting now Disease control Sponsor: Northside Hospital, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a reduced-intensity stem cell transplant for people with blood cancers like leukemia or lymphoma. The approach uses lower doses of chemotherapy and radiation before a half-matched donor transplant. Researchers hope this gentler method will help the body accept the new cells while lowering the chance of the cancer coming back. The study is currently recruiting 20 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fludarabine and total body irradiation followed by stem cell transplant
What this could lead to: If successful, this could offer a safer transplant option for people with blood cancers, reducing the risk of graft rejection and relapse.
What could go wrong: This is a small, early-phase trial with only 20 participants. The reduced-intensity approach may still carry risks like infection, graft failure, or relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

Caitlin Guzowski
RECRUITING

Atlanta, Georgia, 30342, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.